Add to ORKGBACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy. CASE PRESENTATION: We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens. CONCLUSION: This highly refractory pre-B Ph(-) ALL was induced to complete remission after one course of single agent blinatumomab
Introduction. MRD in ALL is defined as detection of leukemic cells in bone marrow by polymerase chai...
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unf...
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse ...
BACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (A...
Background The current standard of care for relapsed and refractory acute lymphoblastic leukemia (AL...
Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hema...
Purpose Few therapeutic options are available for patients with Philadelphia chromosome–positive (Ph...
Lindsey Hathaway,1 Jeremy Michael Sen,2 Michael Keng1 1Department of Medicine, Division of Hematolog...
Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that med...
Purpose: Few therapeutic options are available for patients with Philadelphia chromosome-positive (P...
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymp...
In a phase 3 clinical study of heavily pretreated adults with relapsed/refractory (R/R) acute lympho...
Purpose Few therapeutic options are available for patients with Philadelphia chromosome-positive (Ph...
BACKGROUND Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T ce...
Background: A single-arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bisp...
Introduction. MRD in ALL is defined as detection of leukemic cells in bone marrow by polymerase chai...
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unf...
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse ...
BACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (A...
Background The current standard of care for relapsed and refractory acute lymphoblastic leukemia (AL...
Patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hema...
Purpose Few therapeutic options are available for patients with Philadelphia chromosome–positive (Ph...
Lindsey Hathaway,1 Jeremy Michael Sen,2 Michael Keng1 1Department of Medicine, Division of Hematolog...
Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that med...
Purpose: Few therapeutic options are available for patients with Philadelphia chromosome-positive (P...
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymp...
In a phase 3 clinical study of heavily pretreated adults with relapsed/refractory (R/R) acute lympho...
Purpose Few therapeutic options are available for patients with Philadelphia chromosome-positive (Ph...
BACKGROUND Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T ce...
Background: A single-arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bisp...
Introduction. MRD in ALL is defined as detection of leukemic cells in bone marrow by polymerase chai...
Background: Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unf...
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse ...